Affiliation:
1. Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
2. Department of Clinical Biochemistry, Auckland City Hospital, Auckland, New Zealand
Abstract
Abstract
Background: Plasma concentrations of procollagen peptides are decreased in osteogenesis imperfecta (OI), whereas other bone formation markers may be increased. We examined the utility of combining these markers in the diagnosis of OI in adults.
Methods: We measured plasma concentrations of procollagen-1 N-peptide (P1NP), osteocalcin, and bone alkaline phosphatase in 24 patients with nondeforming OI, 25 patients with low bone mass due to other causes, and 38 age- and sex-matched controls. The discriminant ability of various test combinations was assessed by the construction of ROC curves.
Results: The median (range) ratio of osteocalcin to P1NP was significantly greater in patients with type I OI [1.75 (0.80–3.86)] than in controls [0.59 (0.34–0.90)] and patients with other causes of low bone mass [0.48 (0.05–1.38); P <0.0001]. This ratio allowed nearly complete differentiation between healthy controls and patients with type I OI, but not patients with type IV OI. With a cutoff of 0.97 for osteocalcin:P1NP, the sensitivity and specificity were maximized at 95% (95% CI 76%–100%) and 88% (69%–97%), respectively, for patients with other causes of low bone mass vs those with type I OI only. For patients with other causes of low bone mass vs all OI patients, sensitivity and specificity were 83% (63%–95%) and 88% (69%–97%), respectively. The addition of bone alkaline phosphatase data did not improve the discriminant ability of the osteocalcin:P1NP ratio.
Conclusions: The osteocalcin:P1NP ratio is a sensitive and specific test for type I OI in adults, but it has less utility in the diagnosis of other types of nondeforming OI.
Funder
Health Research Council of New Zealand
Publisher
Oxford University Press (OUP)
Subject
Biochemistry (medical),Clinical Biochemistry
Reference22 articles.
1. Shapiro JR. Osteogenesis imperfecta and other defects of bone development as occasional causes of adult osteoporosis. Marcus R Feldman D Kelsey J eds. Osteoporosis, 2nd ed2001:271-301 Academic Press San Diego, CA. .
2. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet1979;16:101-116.
3. Byers PH, Wallis GA, Willing MC. Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet1991;28:433-442.
4. Delmas PD. Biochemical markers for the assessment of bone turnover. Riggs BL Melton LJ eds. Osteoporosis: Etiology, Diagnosis and Management 2nd ed. 1995:319-333 Lippincott-Raven Philadelphia, PA. .
5. Whyte MP. Osteogenesis imperfecta. Favus MJ eds. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed2003:470-473 American Society for Bone and Mineral Research Washington, DC. .
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献